Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms

Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms. The primary objective of this study is to evaluate the 14- and 28-day mortality associated with cefiderocol. We perfo...

Full description

Bibliographic Details

Published in:	Antibiotics
Main Authors:	Monirul I. Sajib, Melinda Monteforte, Roderick Go
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Subjects:	cefiderocol gram-negative infection multidrug-resistant infection
Online Access:	https://www.mdpi.com/2079-6382/12/5/936